|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||20.56 - 23.19|
|52 Week Range||20.55 - 41.57|
|Beta (3Y Monthly)||2.38|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Medicines Company (MDCO) suffers a wider-than-expected loss in Q3. At the same time, the company posts negative revenues.
Alnylam (ALNY) incurs wider-than-expected loss year over year in the third quarter of 2018 and reiterates guidance for the year.
Medicines Co. (MDCO) delivered earnings and revenue surprises of -45.83% and -189.72%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Parsippany, New Jersey-based company said it had a loss of 75 cents per share. Losses, adjusted for one-time gains and costs, came to 70 cents per share. The results did not meet Wall Street expectations. ...
Investors are launching Medicines Co. spinout Qpex Biopharma Inc. with $33 million in Series A financing.
Mallinckrodt (MNK) gets $26 million for additional funding from BARDA for pediatric studies of StrataGraft skin tissue in thermal burns.
The Medicines Company (MDCO) gets Independent Data Monitoring Committee's recommendation to continue late-stage inclisiran studies as planned and designed.
Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.
According to the GuruFocus All-in-One Screener, the following stocks with market caps over $5 billion look cheap since they are trading with low price-sales ratios. Olin Corp. (OLN) is trading around $30.27 with a price-sales ratio of 0.8, a price-earnings ratio of 8.2 and a forward price-earnings ratio of 11.6. The company has a market cap of $5.06 billion and the stock price has risen at an annualized rate of 5% over the last 10 years.
Medicines Co. (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam Pharmaceuticals’ (ALNY) interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.